- Home
- LXEO
as 11-20-2024 4:00pm EST
Stocks
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 314.1M | IPO Year: | 2023 |
| Target Price: | $22.71 | AVG Volume (30 days): | 623.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.77 - $22.33 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Lexeo Therapeutics Inc. (LXEO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Nov 11 '24 | Sell | $7.82 | 2,500 | $19,556.75 | 120,695 | |
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Oct 10 '24 | Sell | $8.10 | 5,000 | $40,495.50 | 120,695 | |
| Townsend Richard Nolan | LXEO | Chief Executive Officer | Sep 10 '24 | Sell | $10.65 | 5,000 | $53,273.50 | 120,695 |
Latest Lexeo Therapeutics Inc. News
LXEO Breaking Stock News: Dive into LXEO Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation
GlobeNewswire
8 days ago
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
MT Newswires
22 days ago
Lexeo Therapeutics Sees 'Positive' Interim Results for LX1001 to Treat APOE4-Linked Alzheimer's Disease
GlobeNewswire
22 days ago
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire
a month ago
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference
GlobeNewswire
3 months ago
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
3 months ago
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Zacks
4 months ago
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Compare LXEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXEO Lexeo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.